ReviewMolecular biology reports2022
General guidelines for CRISPR/Cas-based genome editing in plants.
Review in Molecular biology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- A rapid Agrobacterium rhizogenes-mediated transient expression for assessing sgRNA efficiency in CRISPR-Act3.0 in tomato.Plant cell reports · 2026Article
- From Lab to Field: CRISPRing Major CultivatedInternational journal of molecular sciences · 2026Review
- Role of CRISPR in bioremediation of heavy metal(loid): a breakthrough in environmental biotechnology.World journal of microbiology & biotechnology · 2026Review
- Enhancing cereal productivity via nitrogen use efficiency: from conventional breeding to modern genomics.Frontiers in genetics · 2026Review
- Review
- High-temperature stress in strawberry: understanding physiological, biochemical and molecular responses.Planta · 2024Review
- Impact of predictive selection of LbCas12a CRISPR RNAs upon on- and off-target editing rates in soybean.Plant direct · 2024Article
- SiMul-db: a database of single and multi-target Cas9 guides for hazelnut editing.Frontiers in genetics · 2024Article
- Application of CRISPR-Cas System to Mitigate Superbug Infections.Microorganisms · 2023Review
- Development of Highly Efficient Resistance toInternational journal of molecular sciences · 2023Article
- Recalcitrance to transformation, a hindrance for genome editing of legumes.Frontiers in genome editing · 2023Review
- Genome editing for healthy crops: traits, tools and impacts.Frontiers in plant science · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CRISPR (clustered regularly interspaced short palindromic repeats)/Cas (CRISPR-associated) technology is a versatile genome editing tool that has been used to improve agriculturally important plant traits. Due to its precision, CRISPR/Cas9 is more effective than either conventional plant breeding methods or standard genetic engineering approaches for the rapid development of new varieties resilient to climate change. In addition to knowledge in tissue culture-based plant transformation, effective gene-specific single guide RNA (sgRNA) design, prediction of its off-target effect and utilization of vectors, promoters, Cas proteins and terminators is required for CRISPR/Cas9. Various bioinformatics tools are available for the best sgRNA design and screening of the off-targets. Various tools are used in the delivery of CRISPR/Cas components into cells and the genome. Moreover, some recent studies proved the simultaneous silencing of different paralogs in the same family or several genes working in the same pathway by using multiple-target sgRNA designs. This review summarizes the type of promoters, Cas proteins, recognition sequences, and terminators available for the development of knock-out and overexpression plant lines. It also provides a general guideline for the development of genome-edited plants from the design of sgRNAs to the selection of non-transgenic genome-edited T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.